Skip to content

US · NEO · MEDICAL - DIAGNOSTICS & RESEARCH

NeoGenomics, Inc. (NEO) intrinsic value and stock valuation

$14.82as of 2026-11-21 · Mkt cap 404.18M

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

NeoGenomics, Inc. DCF and intrinsic value

InvestorsCraft values NEO with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from NEO’s statements →

NeoGenomics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Fort Myers, FL 33912 neogenomics.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$727.3M+10.4% 5y CAGRd
20112025
Net income
-$-108.03M
20112025
Free cash flow
-$-21.78M
20112025
Total equity
$836.6M+3.8% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$727.3M$660.6M$591.6M$509.7M$484.3M
Operating income-$-66.08M-$-92.11M-$-107.74M-$-157.62M-$-118.75M
Net income-$-108.03M-$-78.73M-$-87.97M-$-144.25M-$-8.35M
EPSd-$-4.22M-$-3.11M-$-3.5M-$-5.81M-$-348.06K
Operating cash flow$5.23M$7.02M-$-1.95M-$-65.99M-$-26.72M
Capital expenditure-$-27.01M-$-41.06M-$-28.75M-$-30.89M-$-64.14M
Free cash flow-$-21.78M-$-34.04M-$-30.7M-$-96.88M-$-90.86M
Total assets$1.36B$1.64B$1.68B$1.74B$1.87B
Total debt$472.3M$605.3M$611.7M$610.9M$612.8M
Net debt$312.7M$238.3M$269.2M$347.8M$296M
Total equity$836.6M$902.3M$941.5M$998M$1.11B
Cash and short-term investments$159.6M$386.8M$415.2M$438M$515.4M
Income statement
20252024202320222021
Revenue$727.3M$660.6M$591.6M$509.7M$484.3M
Cost of revenue$444.8M$370.5M$347M$321.8M$297.3M
Gross profit$282.5M$290.1M$244.6M$187.9M$187.1M
Research and development expenses$37.1M$31.2M$27.3M$30.3M$21.9M
Selling, general and administrative expenses$365.3M$310.5M$280M$277.9M$283.9M
Other expenses-$-53.8M$40.6M$45.1M$37.3M$0.00
Operating expenses$348.6M$382.2M$352.3M$345.5M$305.8M
Cost and expenses$793.4M$752.7M$699.4M$667.4M$603.1M
Interest income$9.07M$18.4M$16.9M$6.08M$3.14M
Interest expense$3.75M$6.62M$6.91M$7.58M$8.22M
Depreciation and amortization$67.8M$72.6M$72.6M$69.4M$53.4M
Ebitda-$-38.69M-$-1.51M-$-17.61M-$-82.33M$46.5M
Operating income-$-66.08M-$-92.11M-$-107.74M-$-157.62M-$-118.75M
Total other income/expenses, net-$-44.19M$11.4M$10.6M-$-1.72M$103.7M
Income before tax-$-110.27M-$-80.67M-$-97.1M-$-159.34M-$-15.07M
Income tax expense-$-2.24M-$-1.95M-$-9.13M-$-15.09M-$-6.73M
Net income-$-108.03M-$-78.73M-$-87.97M-$-144.25M-$-8.35M
Weighted average shares outstanding$25.6M$25.3M$25.1M$24.8M$24M
Weighted average diluted shares outstanding$25.6M$25.3M$25.1M$24.8M$24M
Balance sheet
20252024202320222021
Cash and short-term investments$159.6M$386.8M$415.2M$438M$515.4M
Net receivables$159.2M$150.5M$131.3M$119.7M$112.1M
Inventory$28.6M$26.8M$24.2M$24.3M$23.4M
Total current assets$376.3M$596M$596.8M$605.3M$681.5M
Property, plant and equipment, net$163.3M$173.7M$183.8M$198.6M$211.7M
Goodwill and intangible assets$810.9M$862.5M$895.9M$931M$969.4M
Long-term investments$0.00$0.00$0.00$30K$240K
Total non-current assets$983.5M$1.04B$1.08B$1.13B$1.19B
Total assets$1.36B$1.64B$1.68B$1.74B$1.87B
Accounts payable$23.1M$21.6M$20.3M$20.5M$17.9M
Short-term debt$4.78M$204.2M$5.61M$6.65M$9.15M
Deferred revenue$0.00$410K$2.13M$7.56M$5.19M
Total current liabilities$88.3M$301.2M$96.3M$89.9M$87.2M
Long-term debt$467.5M$401.2M$606.1M$604.3M$604.8M
Deferred revenue, non-current$390K$0.00$0.00$20K$920K
Total non-current liabilities$435M$434.5M$643.4M$652.1M$674.3M
Capital lease obligations$62.8M$64.2M$73.5M$75.6M$80.3M
Total liabilities$523.3M$735.7M$739.7M$742M$761.5M
Common stock$130K$130K$130K$130K$120K
Retained earnings-$-433.81M-$-325.78M-$-247.06M-$-159.09M-$-14.84M
Accumulated other comprehensive income (loss)$0.00-$-210K-$-1.67M-$-3.9M-$-640K
Total equity$836.6M$902.3M$941.5M$998M$1.11B
Total investments$0.00$19.8M$72.7M$174.8M$198.6M
Total debt$472.3M$605.3M$611.7M$610.9M$612.8M
Net debt$312.7M$238.3M$269.2M$347.8M$296M
Cash flow statement
20252024202320222021
Net income-$-108.03M-$-78.73M-$-87.97M-$-144.25M-$-8.35M
Depreciation and amortization$67.8M$72.6M$72.6M$69.4M$53.4M
Stock-based compensation$41.3M$33.4M$24.6M$24.7M$22.5M
Change in working capital-$-32.09M-$-32.63M-$-25.49M-$-31.7M-$-4.6M
Accounts receivable-$-6.18M-$-19.31M-$-11.52M-$-7.58M-$-4.69M
Inventory-$-1.54M-$-2.7M-$-450K-$-1.1M$1.63M
Accounts payable-$-4.69M-$-4M-$-4.55M$2.79M$19.3M
Net cash provided by operating activities$5.23M$7.02M-$-1.95M-$-65.99M-$-26.72M
Investments in property, plant and equipment-$-27.01M-$-41.06M-$-28.75M-$-30.89M-$-64.14M
Acquisitions, net-$-6.45M$0.00$0.00$0.00-$-419.4M
Net cash used for investing activities-$-12.34M$12.9M$76.7M$520K-$-632.37M
Common stock issued$960K$4.65M$4.62M$12.6M$423.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-200.29M$4.65M$4.55M$11.8M$725.3M
Net change in cash-$-207.39M$24.5M$79.3M-$-53.65M$66.2M
Cash at end of period$159.6M$367M$342.5M$263.2M$316.8M
Operating cash flow$5.23M$7.02M-$-1.95M-$-65.99M-$-26.72M
Capital expenditure-$-27.01M-$-41.06M-$-28.75M-$-30.89M-$-64.14M
Free cash flow-$-21.78M-$-34.04M-$-30.7M-$-96.88M-$-90.86M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About NeoGenomics, Inc.

        NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.

        CEO
        Anthony Zook
        Employees
        2.5K
        Beta
        1.74

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of NeoGenomics, Inc. (NEO)?

        NeoGenomics, Inc. (NEO) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is NEO undervalued?

        NEO trades at a price of $14.82 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.